151 related articles for article (PubMed ID: 26515606)
1. NDRG4 stratifies the prognostic value of body mass index in colorectal cancer.
Zheng J; Li Y; Zhu S; Li J; Zhao Q; Ji G; Wang W; Chu D
Oncotarget; 2016 Jan; 7(2):1311-22. PubMed ID: 26515606
[TBL] [Abstract][Full Text] [Related]
2. NDRG4, a novel candidate tumor suppressor, is a predictor of overall survival of colorectal cancer patients.
Chu D; Zhang Z; Zhou Y; Li Y; Zhu S; Zhang J; Zhao Q; Ji G; Wang W; Zheng J
Oncotarget; 2015 Apr; 6(10):7584-96. PubMed ID: 25749388
[TBL] [Abstract][Full Text] [Related]
3. Tumor TP53 expression status, body mass index and prognosis in colorectal cancer.
Morikawa T; Kuchiba A; Liao X; Imamura Y; Yamauchi M; Qian ZR; Nishihara R; Sato K; Meyerhardt JA; Fuchs CS; Ogino S
Int J Cancer; 2012 Sep; 131(5):1169-78. PubMed ID: 22038927
[TBL] [Abstract][Full Text] [Related]
4. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer.
Melotte V; Lentjes MH; van den Bosch SM; Hellebrekers DM; de Hoon JP; Wouters KA; Daenen KL; Partouns-Hendriks IE; Stessels F; Louwagie J; Smits KM; Weijenberg MP; Sanduleanu S; Khalid-de Bakker CA; Oort FA; Meijer GA; Jonkers DM; Herman JG; de Bruïne AP; van Engeland M
J Natl Cancer Inst; 2009 Jul; 101(13):916-27. PubMed ID: 19535783
[TBL] [Abstract][Full Text] [Related]
5. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis.
Mima K; Nishihara R; Qian ZR; Cao Y; Sukawa Y; Nowak JA; Yang J; Dou R; Masugi Y; Song M; Kostic AD; Giannakis M; Bullman S; Milner DA; Baba H; Giovannucci EL; Garraway LA; Freeman GJ; Dranoff G; Garrett WS; Huttenhower C; Meyerson M; Meyerhardt JA; Chan AT; Fuchs CS; Ogino S
Gut; 2016 Dec; 65(12):1973-1980. PubMed ID: 26311717
[TBL] [Abstract][Full Text] [Related]
6. Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value.
Kwon MJ; Kim JW; Jung JP; Cho JW; Nam ES; Cho SJ; Kim JS; Park HR; Min SK; Seo J; Min KW; Kim DH; Jeon JY
Hum Pathol; 2016 Apr; 50():90-100. PubMed ID: 26997442
[TBL] [Abstract][Full Text] [Related]
7. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis.
Kalady MF; Dejulius KL; Sanchez JA; Jarrar A; Liu X; Manilich E; Skacel M; Church JM
Dis Colon Rectum; 2012 Feb; 55(2):128-33. PubMed ID: 22228154
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF.
Mosakhani N; Lahti L; Borze I; Karjalainen-Lindsberg ML; Sundström J; Ristamäki R; Osterlund P; Knuutila S; Sarhadi VK
Cancer Genet; 2012 Nov; 205(11):545-51. PubMed ID: 23098991
[TBL] [Abstract][Full Text] [Related]
9. NDRG4 in gastric cancer determines tumor cell proliferation and clinical outcome.
Zhang Z; She J; Yang J; Bu X; Ji G; Zhu S; He S; Chu D
Mol Carcinog; 2018 Jun; 57(6):762-771. PubMed ID: 29500881
[TBL] [Abstract][Full Text] [Related]
10. High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort.
Sorbye H; Dragomir A; Sundström M; Pfeiffer P; Thunberg U; Bergfors M; Aasebø K; Eide GE; Ponten F; Qvortrup C; Glimelius B
PLoS One; 2015; 10(6):e0131046. PubMed ID: 26121270
[TBL] [Abstract][Full Text] [Related]
11. Prediagnosis Plasma Adiponectin in Relation to Colorectal Cancer Risk According to KRAS Mutation Status.
Inamura K; Song M; Jung S; Nishihara R; Yamauchi M; Lochhead P; Qian ZR; Kim SA; Mima K; Sukawa Y; Masuda A; Imamura Y; Zhang X; Pollak MN; Mantzoros CS; Harris CC; Giovannucci E; Fuchs CS; Cho E; Chan AT; Wu K; Ogino S
J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26598515
[TBL] [Abstract][Full Text] [Related]
12. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy.
Teng HW; Huang YC; Lin JK; Chen WS; Lin TC; Jiang JK; Yen CC; Li AF; Wang HW; Chang SC; Lan YT; Lin CC; Wang HS; Yang SH
J Surg Oncol; 2012 Aug; 106(2):123-9. PubMed ID: 22331825
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of patients with microsatellite-unstable colorectal carcinomas depend on L1 methylation level.
Rhee YY; Kim MJ; Bae JM; Koh JM; Cho NY; Juhnn YS; Kim D; Kang GH
Ann Surg Oncol; 2012 Oct; 19(11):3441-8. PubMed ID: 22618722
[TBL] [Abstract][Full Text] [Related]
14. GATA binding protein 2 overexpression is associated with poor prognosis in KRAS mutant colorectal cancer.
Xu K; Wang J; Gao J; Di J; Jiang B; Chen L; Wang Z; Wang A; Wu F; Wu W; Shen L; Su X
Oncol Rep; 2016 Sep; 36(3):1672-8. PubMed ID: 27460045
[TBL] [Abstract][Full Text] [Related]
15. FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
Personeni N; Rimassa L; Verusio C; Barni S; Rubino L; Bozzarelli S; Villa E; Carnaghi C; Tronconi MC; Gerardi C; Galli F; Floriani I; Destro A; Raschioni C; Labianca R; Santoro A
Clin Colorectal Cancer; 2015 Sep; 14(3):162-9. PubMed ID: 25861836
[TBL] [Abstract][Full Text] [Related]
16. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer.
Ogino S; Kawasaki T; Kirkner GJ; Ogawa A; Dorfman I; Loda M; Fuchs CS
J Pathol; 2006 Oct; 210(2):147-54. PubMed ID: 16850502
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA
Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292
[TBL] [Abstract][Full Text] [Related]
19. Tumor LINE-1 methylation level and colorectal cancer location in relation to patient survival.
Mima K; Nowak JA; Qian ZR; Cao Y; Song M; Masugi Y; Shi Y; da Silva A; Gu M; Li W; Hamada T; Zhang X; Wu K; Meyerhardt JA; Baba H; Giovannucci EL; Chan AT; Fuchs CS; Ogino S; Nishihara R
Oncotarget; 2016 Aug; 7(34):55098-55109. PubMed ID: 27391152
[TBL] [Abstract][Full Text] [Related]
20. Metabolic factors and the risk of colorectal cancer by KRAS and BRAF mutation status.
Myte R; Gylling B; Häggström J; Häggström C; Zingmark C; Löfgren Burström A; Palmqvist R; Van Guelpen B
Int J Cancer; 2019 Jul; 145(2):327-337. PubMed ID: 30613980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
